GLP-1 Medications and Cancer Risk: What We Know So Far

GLP-1 medications like semaglutide and tirzepatide may reduce the risk of certain obesity-related cancers while carrying a theoretical concern about one specific cancer type. The overall picture from current research is more reassuring than alarming, but it deserves a clear-eyed look. Here’s what patients and providers are working with right now.

Why Cancer and Obesity Are Connected

Before getting into what GLP-1 medications do or don’t do to cancer risk, it’s worth understanding why this question matters in the first place.

Obesity is a well-established risk factor for at least 13 types of cancer, according to the National Cancer Institute. These include cancers of the breast (postmenopausal), colon, endometrium, kidney, liver, esophagus, stomach, pancreas, thyroid, and several others. The mechanisms connecting obesity to cancer are multiple: chronic inflammation, elevated insulin and insulin-like growth factor levels, excess estrogen produced by adipose tissue, and immune dysfunction all contribute to an environment where cancer cells are more likely to develop and proliferate.

Losing a meaningful amount of weight, by any means, generally reduces these cancer-promoting conditions. This is why the question of whether GLP-1 medications specifically affect cancer risk is scientifically interesting beyond just the pharmacological effects of the drugs themselves.

The Potential Cancer Risk Reduction Signal

Several observational studies have suggested that GLP-1 receptor agonists may reduce the incidence of obesity-related cancers. The most notable of these was a large retrospective analysis published in JAMA Oncology in 2024, which examined health records from more than 1.6 million patients with type 2 diabetes and obesity. Researchers compared those taking semaglutide against those taking insulin and found that semaglutide use was associated with significantly lower rates of 10 out of 13 obesity-related cancers examined.

The reductions were largest for gallbladder cancer, meningioma, and pancreatic cancer, though the absolute risk reductions for less common cancers should be interpreted carefully given smaller patient numbers in those groups. For more common cancers like colorectal and endometrial cancer, the associations were also meaningful.

Whether these associations reflect a direct anti-cancer effect of semaglutide, a consequence of weight loss and improved metabolic health, or some combination of both is not yet clear. GLP-1 receptors are present on various cell types throughout the body, and some laboratory research has shown that GLP-1 receptor activation can inhibit tumor cell growth and promote apoptosis (programmed cell death) in certain cancer lines. This raises the possibility of direct anti-tumor effects, but translating cell culture findings to human clinical outcomes requires considerably more evidence.

Understanding how GLP-1 medications affect inflammation is relevant here, since chronic inflammation is one of the key pathways connecting obesity to cancer development.

The Thyroid Cancer Question

The one area where GLP-1 medications carry a theoretical cancer concern is thyroid cancer, specifically a rare type called medullary thyroid carcinoma (MTC).

This concern originated in rodent studies conducted during the development of GLP-1 drugs, where high-dose, long-duration exposure to GLP-1 receptor agonists caused C-cell tumors in rats and mice. Because of this, semaglutide, tirzepatide, and related medications carry a black box warning contraindicating their use in patients with a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2).

Here’s the important context: rodent thyroid C-cells express GLP-1 receptors at much higher densities than human thyroid C-cells do. The mechanism that drove tumor formation in rodents may not apply meaningfully to humans at therapeutic doses. To date, large-scale human epidemiological data has not confirmed an elevated rate of MTC in patients using GLP-1 medications. Post-marketing surveillance data from millions of patients has not produced a clear signal of increased thyroid cancer incidence.

That said, the theoretical risk is real enough to warrant the contraindication for high-risk individuals, and providers appropriately screen for thyroid cancer history before prescribing these medications.

It’s also worth noting that the JAMA Oncology study mentioned above found no statistically significant association between semaglutide use and thyroid cancer overall, including papillary thyroid cancer, which is far more common than MTC.

Pancreatic Cancer: A Nuanced Picture

Pancreatic cancer deserves separate discussion because it appears in two places in this conversation: as a cancer that semaglutide may help reduce the risk of, and as a concern raised in earlier GLP-1 research.

Earlier studies examining the GLP-1 drug class raised questions about whether these medications might increase pancreatitis risk, and by extension, pancreatic cancer risk over the long term. The pancreatitis question is addressed separately in the article on Ozempic and pancreatitis, but the short answer is that large randomized trials have not confirmed a meaningful elevation in pancreatitis or pancreatic cancer risk at therapeutic doses.

The more recent JAMA Oncology data actually showed a reduced incidence of pancreatic cancer in semaglutide users compared to insulin users, which runs counter to the earlier theoretical concern. This doesn’t fully resolve the question, since insulin users may differ from the general population in ways that affect baseline pancreatic cancer risk. But it adds to the weight of evidence suggesting that GLP-1 medications do not meaningfully elevate pancreatic cancer risk and may reduce it.

What About Colorectal Cancer Specifically?

Colorectal cancer has received particular attention in the GLP-1 cancer literature because it is both common and strongly associated with obesity. A study published in JAMA Network Open in 2023 found that GLP-1 receptor agonist use in patients with type 2 diabetes was associated with a significantly lower risk of colorectal cancer compared to several other diabetes medication classes.

The mechanisms proposed include reduced insulin levels (high insulin promotes colon cell proliferation), decreased systemic inflammation, improved gut motility, and potential direct effects of GLP-1 receptor activation on colon epithelial cells. Whether how GLP-1 medications affect gut health and microbiome plays a role in colorectal cancer risk is an open question that future research may address.

How to Think About This as a Patient

A few practical takeaways for patients considering or currently using GLP-1 medications:

The Overall Signal Is Reassuring

For most patients, current evidence suggests GLP-1 medications do not increase cancer risk and may meaningfully reduce the risk of several obesity-related cancers. The thyroid cancer concern applies to a specific high-risk population and is appropriately screened for at the time of prescribing.

Weight Loss Itself Is Cancer-Protective

Even if GLP-1 medications had no direct effect on cancer biology, the substantial weight loss they produce would be expected to reduce cancer risk through the metabolic pathways described above. Consider this scenario: a patient with obesity loses 18% of body weight over 12 months on tirzepatide. Their insulin levels normalize, systemic inflammation drops, and estrogen production from adipose tissue decreases. Each of these changes independently reduces cancer-promoting conditions in the body.

This Research Is Still Evolving

The studies available so far are largely observational, and most were conducted in patients with type 2 diabetes rather than the broader obesity population now using these medications. Randomized controlled trials with cancer endpoints are difficult to conduct given the long timelines involved. As GLP-1 medications are used by more people over longer periods, the epidemiological picture will become clearer.

Routine Cancer Screening Remains Essential

GLP-1 medications are not a substitute for age-appropriate cancer screening. Colonoscopies, mammograms, cervical screenings, and other recommended tests remain important regardless of what weight loss medication you’re taking.

Ready to Explore Your Options?

If you’re considering GLP-1 treatment and want to understand whether it fits your health history, TrimRx connects you with licensed providers who can evaluate your full picture. You can explore compounded semaglutide or compounded tirzepatide as options, or start your assessment to see if you’re a candidate.

This information is for educational purposes and is not medical advice. Consult with a healthcare provider before starting any medication. Individual results may vary.